GRIK2 was first reported in relation to autosomal dominant complex neurodevelopmental disorder in 2016 (Guzman et al., PMID: 28180184). Clinical features include intellectual disability, developmental and speech delay, motor delay, hypotonia, hypertonia, visual impairment, seizures, abnormal myelination, and autism spectrum disorder. Variants in GRIK2 have also been reported with autosomal recessive complex neurodevelopmental disorder. This gene-disease relationship has been assessed separately.
A pathogenic de novo missense variant in GRIK2 (c.1969G>A [p.Ala657Thr]) was first identified in a 2016 study by Guzman et al. (PMID: 28180184) via trio whole-exome sequencing of a 10 year-old proband who displayed ataxia, motor and speech delay, and intellectual disability, and her unaffected parents. Subsequently, 5 additional unrelated probands harboring the same variant were described in a 2021 study (Stolz et al., PMID: 34375587) which performed trio whole-exome sequencing on the probands and their parents, including the proband from the 2016 study. In this study, two additional GRIK2 missense variants (c.1979C>A [p.Thr660Lys] and c.1979C>G [p.Thr660Arg]) were also identified. All three variants were de novo missense variants affecting the GluK2a protein M3 domain which forms the ion channel pore, were found in multiple unrelated heterozygous probands via trio whole-exome sequencing of the probands and their parents, and each proband displayed several neurodevelopmental symptoms such as intellectual disability, developmental and speech delay, motor delay, hypotonia, hypertonia, visual impairment, seizures, abnormal myelination, and autism spectrum disorder. Electrophysiological experiments performed in cell culture as part of the 2021 study demonstrated complex effects on functional properties and membrane localization of homomeric and heteromeric KARs, in particular, markedly slowed gating kinetics, thus supporting the clinical phenotypes observed in the probands.
An additional variant, c.2003T>C [p.Ile668Thr], with a similar autosomal dominant inheritance pattern and gain of function molecular mechanism was identified in one proband via identical methods, and also described in the 2021 study (PMID: 34375587). However, compared to the other three variants, this variant affects a different protein domain (M3-S2 linker), the proband only had autism spectrum disorder, and electrophysiological molecular experiments displayed a milder phenotype. Therefore, we did not include the c.2003T>C [p.Ile668Thr] in the scoring for this curation.
Based on the studies described, GRIK2 variants affecting the M3 protein domain result in a gain of function inherited in an autosomal dominant pattern, and are associated with a spectrum of neurodevelopmental disorders. Based on the volume of evidence in the literature, the maximum score for genetic evidence (12 points) has been reached.
In summary, there is definitive evidence to support the relationship between autosomal dominant gain of function missense variants in the GRIK2 M3 domain and complex neurodevelopmental disorder. This classification was approved by the ClinGen Intellectual Disability and Autism Gene Curation Expert Panel on February 10, 2022 (SOP Version 8).
The GenCC data are available free of restriction under a CC0 1.0 Universal (CC0 1.0) Public Domain Dedication. The GenCC requests that you give attribution to GenCC and the contributing sources whenever possible and appropriate. The accepted Flagship manuscript is now available from Genetics in Medicine (https://www.gimjournal.org/article/S1098-3600(22)00746-8/fulltext).
The information on this website is not intended for direct diagnostic use or medical decision-making without review by a genetics professional. Individuals should not change their health behavior solely on the basis of information contained on this website. The GenCC does not independently verify the submitted information. Though the information is obtained from sources believed to be reliable, no warranty, expressed or implied, is made regarding accuracy, adequacy, completeness, reliability or usefulness of any information. This disclaimer applies to both isolated and aggregate uses of the information. The information is provided on an "as is" basis, collected through periodic submission and therefore may not represent the most up-to-date information from the submitters. If you have questions about the medical relevance of information contained on this website, please see a healthcare professional; if you have questions about specific gene-disease claims, please contact the relevant sources; and if you have questions about the representation of the data on this website, please contact gencc@thegencc.org.